Suppr超能文献

通过癌抗原125(CA 125)同时评估卵巢癌上皮细胞功能以及通过III型前胶原氨基端前肽(PIIINP)评估基质细胞活性。

Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.

作者信息

Tomás C, Penttinen J, Risteli J, Risteli L, Kauppila A

机构信息

Department of Obstetrics and Gynaecology, University of Oulu, Finland.

出版信息

Ann Med. 1990 Apr;22(2):115-21. doi: 10.3109/07853899009147253.

Abstract

Serum concentrations of CA 125 and the aminoterminal propeptide of type III procollagen (PIIINP) were measured in 50 patients with clinical stage I or II (N = 16) and stage III or IV (N = 34) ovarian carcinoma before and during cytotoxic chemotherapy. Initially pathological concentrations of CA 125 were found in 92% of all patients and 100% of those in clinical stages II, III and IV. The concentration of PIIINP was at pathological levels in 71% of patients. Serum concentrations of CA 125 (P = 0.04) and PIIINP (P = 0.005) were higher in stages III and IV than in stages I and II. Initial concentration of PIIINP, but not of CA 125, was significantly (P less than or equal to 0.001) higher in the 19 patients who died of the malignancy than in the 31 patients alive at the end of the follow-up period. There was a significant inverse correlation (P = 0.01) between the initial PIIINP values and the survival time among patients with a poor prognosis. Initial concentration of CA 125 was of no prognostic value. During the follow-up, the serum concentrations of CA 125 and PIIINP correlated closely with clinical changes in the disease. Either or both of the tumour markers increased or remained at pathological levels before clinical relapse in patients who had initially responded. PIIINP was a more accurate marker (84%) than CA 125 (63%) in this respect. The information obtained from CA 125 and PIIINP concentrations was identical in 65% and complementary in 33% of the patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在50例临床分期为I期或II期(N = 16)以及III期或IV期(N = 34)的卵巢癌患者中,于细胞毒性化疗前后测定了血清CA 125和III型前胶原氨基端前肽(PIIINP)的浓度。最初,92%的所有患者以及临床分期为II期、III期和IV期的患者中100%发现CA 125的病理浓度。71%的患者PIIINP浓度处于病理水平。III期和IV期患者的血清CA 125(P = 0.04)和PIIINP(P = 0.005)浓度高于I期和II期。在随访期末死亡的19例恶性肿瘤患者中,PIIINP的初始浓度显著(P≤0.001)高于存活的31例患者,而CA 125则不然。预后不良的患者中,初始PIIINP值与生存时间之间存在显著负相关(P = 0.01)。CA 125的初始浓度无预后价值。在随访期间,血清CA 125和PIIINP浓度与疾病的临床变化密切相关。在最初有反应的患者中,一种或两种肿瘤标志物在临床复发前升高或维持在病理水平。在这方面,PIIINP是比CA 125更准确的标志物(84%对63%)。65%的患者中,从CA 125和PIIINP浓度获得的信息相同,33%互补。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验